3 separate 0.5-mL IM doses administered at 0, 2 & 6 mth. Individual 9-14 yr Alternatively, can be administered according to a 2-dose schedule. 2nd dose: Administer between 5 & 13 mth after 1st dose. If 2nd dose is administered earlier than 5 mth after 1st dose, a 3rd dose should always be administered.
Anaphylactic reactions. Not to be inj intravascularly, SC or intradermally. Not for treatment of cervical, vulvar, vag & anal cancer, high-grade cervical, vulvar, vag & anal dysplastic lesions or genital warts. Not for prevention of progression of other established HPV-related lesions. Not for prevention of lesions due to HPV type vaccine in individuals infected w/ that HPV at the time of vaccination. Syncope. Individuals suffering from acute severe febrile illness; impaired immune responsiveness; thrombocytopenia or any coagulation disorder. May temporarily affect ability to drive & use machines. Vaccination should be postponed during pregnancy.
Sign Out
